首页 > 市场调查报告书 > 製药

临床实验

市场调查报告书

商品编码

1672866

儿科临床试验市场：依阶段、研究设计、治疗领域及地区划分

Pediatric Clinical Trials Market, By Phase, By Study Design, By Therapeutic Area, By Geography

出版日期: 2025年02月07日 | 出版商:

Coherent Market Insights | 英文 313 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2025 年全球儿科临床试验市场规模估计为 192.6 亿美元，预计到 2032 年将达到 370.8 亿美元，2025 年至 2032 年的复合年增长率为 9.8%。

报告范围		报告详细信息
基准年	2024	2025 年市场规模	192.6亿美元
效能资料	2020-2024	预测期	2025-2032
预测期：2025 年至 2032 年复合年增长率	9.80％	2032 年金额预测	370.8亿美元

数字。儿科临床试验市场份额（按地区划分）（%）（2025 年）

近年来，儿科临床试验市场经历了显着的成长。儿童慢性病发病率的不断上升以及对新治疗方案的需求不断增长，推动了儿科临床试验产业的发展。此外，市场上製药公司对开发儿科药物的投资正在增加。人们对罕见疾病认识的提高以及监管机构要求对儿科药物进行临床评估的各种倡议正在扩大市场机会。然而，由于伦理问题、特定年龄的药物代谢、招募挑战以及缺乏对替代终点的共识，进行儿科药物的临床试验比成人试验更为复杂和具有挑战性。随着新治疗方法的出现和公司不断努力开发儿童友善药物，儿科临床试验市场预计将在未来几年内强劲成长。

市场动态

全球儿科临床试验市场的成长得益于儿童慢性病盛行率的上升、对新治疗方法的需求的增加以及简化药物开发流程的监管力度。根据世界卫生组织估计，2021年全球将有超过2亿名儿童受到各种非传染性疾病的影响。鑑于未满足的需求庞大，製药公司正在加大对儿童专用治疗方法的开发投资。美国食品药物管理局（FDA）2012年修正案等有利法规要求对儿科药物进行上市前临床评估，扩大了市场机会。然而，儿科临床研究的复杂性以及缺乏足够的替代终点继续对市场成长产生不利影响。此外，临床试验的高成本以及经验丰富的临床实验的短缺也是更广泛的市场应用障碍。相关人员和研究机构之间持续合作寻求解决问题的新方法可能会支持未来的扩展。

研究的主要特点

本报告对全球儿科临床试验市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模和复合年增长率。

它还强调了各个领域的潜在商机并说明了该市场的有吸引力的投资提案矩阵。

它还提供了关于市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的主要考察。

全球儿科临床试验市场的主要企业根据公司亮点、产品系列、关键亮点、绩效和策略等参数进行分析。

主要企业包括 CSL Behring、赛诺菲、武田药品工业有限公司、Orchard Therapeutics plc.、Pharming Group NV、BioCryst Pharmaceuticals, Inc.、Ionis Pharmaceuticals, Inc.、Attune Pharmaceuticals、Arrowhead Pharmaceuticals, Inc.、Adverum, Inc. Technologo、Technor.T.

本报告的见解将使负责人和公司经营团队能够就未来的产品发布、规模扩大、市场扩张和行销策略做出明智的决策。

全球儿科临床试验市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。

相关人员可以透过全球儿科临床试验市场分析中使用的各种策略矩阵来促进决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 19.26 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	9.80%	2032 Value Projection:	USD 37.08 Bn

The pediatric clinical trials market is witnessing significant growth in recent times. Growing prevalence of chronic diseases among children and rising demand for new treatment options have boosted the pediatric clinical trials industry. Further, the market has witnessed rising investment from pharmaceutical companies for drug development targeting pediatric population. Growing awareness about rare diseases and various initiatives undertaken by regulatory bodies mandating clinical evaluation of drugs for pediatric use have augmented market opportunities. However, conducting clinical trials for pediatric drugs is more complex and challenging than adult trials due to ethical concerns, age specific drug metabolism, difficulty in recruitment, and lack of consensus over surrogate endpoints. Nevertheless, with emerging novel medical therapies and continuous efforts by players towards developing child-friendly drugs, the pediatric clinical trials market is poised to experience strong growth over the forthcoming years.

Market Dynamics:

The global pediatric clinical trials market growth is driven by the rising incidence of chronic diseases among children, growing demand for new treatment modalities, and initiatives undertaken by regulatory bodies to streamline drug development process. In 2021, as per WHO estimates, over 200 million children suffer from various non-communicable illnesses worldwide. High unmet clinical needs have encouraged pharmaceutical companies to boost investments towards developing specialized treatments for pediatric population. Favorable regulations such as the U.S. Food and Drug Administration's amendments Act 2012 have mandated pre-marketing clinical evaluation of drugs for pediatric use, thereby augmenting market opportunities. However, complexities involved in pediatric clinical research and lack of sufficient surrogate endpoints continue to negatively impact market growth. High costs associated with trials and inadequate number of experienced clinical investigators also impede broader market adoption. Nevertheless, continual collaborations between industry players and research organizations to address issues through novel approaches will support future expansion.

Key Features of the Study:

This report provides in-depth analysis of the global pediatric clinical trials market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global pediatric clinical trials market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include CSL Behring, Sanofi, Takeda Pharmaceutical Company Limited, Orchard Therapeutics plc., Pharming Group N.V., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, and CENTOGENE N.V.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global pediatric clinical trials market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pediatric clinical trials market

Market Segmentation

Phase Insights (Revenue, USD Bn, 2019-2032)
- Phase I
- Phase II
- Phase III
- Phase IV
Study Design Insights (Revenue, USD Bn, 2019-2032)
- Treatment Studies
- Observational Studies
Therapeutic Area Insights (Revenue, USD Bn, 2019-2032)
- Respiratory Diseases
- Cardiovascular Diseases
- Neuropsychiatric Conditions
- Oncology
- Diabetes
- Others (Neuropsychiatric Conditions, etc.)
Regional Insights (Revenue, USD Bn, 2019-2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- CSL Behring
- Sanofi
- Takeda Pharmaceutical Company Limited
- Orchard Therapeutics plc.
- Pharming Group N.V.
- BioCryst Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Attune Pharmaceuticals
- Arrowhead Pharmaceuticals, Inc.
- Adverum Biotechnologies, Inc.
- KalVista Pharmaceuticals
- CENTOGENE N.V.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Pediatric Clinical Trials Market, By Phase
- Pediatric Clinical Trials Market, By Study Design
- Pediatric Clinical Trials Market, By Therapeutic Area
- Pediatric Clinical Trials Market, By Region

3. Market Dynamics, Regulations, And Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Epidemiology

4. Global Pediatric Clinical Trials Market, By Phase, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Phase I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Phase II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Phase III
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Phase IV
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Pediatric Clinical Trials Market, By Study Design, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Treatment Studies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Observational Studies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Pediatric Clinical Trials Market, By Therapeutic Area, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Respiratory Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Neuropsychiatric Conditions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Neuropsychiatric Conditions, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Pediatric Clinical Trials Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Phase, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Study Design, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
Latin America
- Introduction
- Market Size and Forecast, By Phase, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Study Design, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Phase, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Study Design, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Phase, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Study Design, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Phase, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Study Design, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Phase, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Study Design, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Sub-region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa

8. Competitive Landscape

CSL Behring
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Orchard Therapeutics plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pharming Group N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
BioCryst Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Ionis Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Attune Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Arrowhead Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Adverum Biotechnologies, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
KalVista Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
CENTOGENE N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

9. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

10. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

儿科临床试验市场：依阶段、研究设计、治疗领域及地区划分